U.S. Stock Futures Hold Steady After S&P 500 and Nasdaq Hit Record Highs 
Middle East Ceasefire Hopes Lift Asian Markets as Oil Prices Retreat 
Why the future of marijuana legalization remains hazy despite high public support 
Oil Prices Surge Amid Middle East Tensions as Global Markets React Cautiously 
Uranium Bull Market Gains Momentum Amid Supply Deficits and Geopolitical Tensions 
J.P. Morgan Downgrades Essity AB on Rising Costs and Weak Earnings Outlook 
RFK Jr. Expands CDC Vaccine Advisory Panel's Scope Amid Legal Battles 
Oil Prices Plunge as Strait of Hormuz Reopens Amid U.S.-Iran Ceasefire Talks 
Huawei Expands Vietnam Presence Through Strategic Partnership with SHB Bank 
Stocks Surge as Strait of Hormuz Reopens, Oil Prices Plunge 
IMF and World Bank Resume Ties with Venezuela, Opening Door to Billions in Funding 
U.S. Officials Express Optimism Over New CDC Director Selection Amid Vaccine Policy Turmoil 
FDA Rejects Review of Moderna’s Flu Vaccine Application, Shares Slide 
Japan Eyes Private Credit as Key Pillar in New Financial Strategy 
Anthropic CEO Meets Trump Officials to Discuss Powerful New AI Model Mythos 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
South Korea's SK Chemicals has partnered with AstraZeneca's Korean affiliate in a contract manufacturing organization (CMO) agreement. SK Chemicals will produce and globally distribute Sidapvia, a new treatment for type 2 diabetes, combining leading active ingredients dapagliflozin and sitagliptin.
Under this agreement, SK Chemicals will be responsible for the manufacturing and global distribution of Sidapvia, a groundbreaking combination of Forxig (dapagliflozin) and sitagliptin. Sidapvia is indicated for adults aged 18 and older with type 2 diabetes, a condition characterized by improper insulin function and high blood sugar levels.
SK Chemicals and AstraZeneca have jointly developed this promising diabetes treatment. While SK Chemicals focuses on manufacturing and distribution, AstraZeneca will be the marketing authorization holder (MAH). They will handle country-specific licensing and marketing efforts, and South Korea has already granted licensing for Sidapvia, making it the first country to do so.
Sidapvia combines two active ingredients, Forxiga and sitagliptin, globally recognized as a leading SGLT-2 inhibitor and top-selling DPP-4 inhibitor. These ingredients work through different mechanisms of action to effectively lower blood glucose levels, offering a viable option for managing complications among diabetic patients.
Ahn Jae-hyun, the CEO of SK Chemicals, expressed utmost confidence in the company's pharmaceutical technology and production capabilities. These capabilities have paved the way for the supply of medicines to numerous countries, and Ahn emphasized the company's plans to foster diverse collaboration opportunities.
The collaboration between SK Chemicals and AstraZeneca began in early 2020, with AstraZeneca providing SK Chemicals with active pharmaceutical ingredients (APIs) and funding research for diabetes treatment development. Subsequently, SK Chemicals took over product research and development and conducted domestic clinical trials. With this new agreement as a starting point, SK Chemicals aims to expand the supply of Sidapvia in Korea and the global market.
This collaboration marks a significant milestone for SK Chemicals and AstraZeneca, solidifying their commitment to advancing diabetes treatment and improving the lives of millions of patients worldwide.
